Exploring the Role of Natural Anti-PD-L1 antibodies in Shaping the Anti-Tumor Immune Response to Neoadjuvant Chemo-Immunotherapy in NSCLC 2308226
Non-small-cell lung cancer (NSCLC) is a major contributor to cancer-related deaths worldwide. Although the introduction of immune checkpoint inhibitors, such as anti-PD-1, has improved patient survival, treatment responses remain heterogeneous, and the complete mechanisms of action are not yet fully understood. O...